Page 2430 - Williams Hematology ( PDFDrive )

2401
2400 Index Index 2401

ADP receptor blockers, 405 contraindications, 2273 plasma exchange. See Plasma exchange
α β blockers, 405–406 direct thrombin inhibitors, 2031t. See also red cell depletion. See Erythrocytapheresis
IIb 3
cyclic adenosine monophosphate Argatroban; Bivalirudin red cell exchange. See Red cell exchange
modulators, 404–405 fibrinolytic therapy. See Fibrinolytic thrombocytapheresis, 433
cyclooxygenase inhibitors, 403–404 therapy Apixaban, 402
for essential thrombocythemia, 1313 heparin. See Heparin adverse effects, 2275t
for myocardial infarction, 2295–2296 indirect factor Xa inhibitors. See clinical studies, 401t
for peripheral artery disease, 2297 Danaparoid; Fondaparinux mechanism of action, 1922
platelet transfusion and, 2385 low-molecular-weight heparin. See for venous thromboembolism, 2274–2275,
thrombin receptor blockers, 406 Low-molecular-weight heparin 2274t, 2275t
for thrombotic thrombocytopenic (LMWH) APL. See Acute promyelocytic leukemia
purpura, 2256 for myocardial infarction, 2295–2296 (APL)
Anti-protein S antibodies, 2187 overview, 393 Aplastic anemia, 513–527
Antiprothrombin antibodies, 2186–2187 platelet function and, 2078 acute myelogenous leukemia and, 1375
Antiretroviral therapy (ART) platelet transfusion and, 2385 clinical features, 519
chemotherapy drugs and, 1249 in pregnancy, 580, 2277 clonal myeloid diseases and, 521
for HIV infection targeted oral anticoagulants. See course and prognosis, 527
adverse effects, 1242, 2281 Apixaban; Dabigatran; Edoxaban; definition, 513
effectiveness, 1242 Rivaroxaban degree of severity, 513, 514t
with Hodgkin lymphoma, 1249 types and function, 394t differential diagnosis, 520–521, 637, 1513
initiation, 1242, 1242t for venous thromboembolism. See Venous epidemiology, 513–514
maternal ingestion, effects on fetus and thrombosis/thromboembolism, etiology and pathogenesis, 514–519, 514t,
newborn, 112t therapy 516f
Anti-(Rh)D, 2005, 2011 vitamin K antagonists. See Warfarin autoimmune disorders in, 518
Antisense DNA, 153 Antithymocyte globulin (ATG) autoreactive cytotoxic T lymphocytes in,
Antisense RNA, 153 for aplastic anemia, 523, 524t, 525f, 525t, 527 515, 516f
Antiswitching therapies, for sickle cell for graft-versus-host disease prophylaxis, drug-related, 515–516
disease, 774–775, 774t 371 iatrogenic, 518–519
Antithrombin (AT), 1959–1960 for hemophagocytic lymphohistiocytosis, pregnancy-related, 518
antibodies, 2186 1115 stromal microenvironment and growth
characteristics, 1916t, 1936 for myelodysplastic syndromes, 1359 factors in, 519
in disseminated intravascular coagulation, for pure red cell aplasia, 544 telomere shortening in, 515
2202 Antitubulins, 325–326 toxic chemicals in, 516–518
functions, 1936–1937, 1936f, 1968, 2202 Antitumor necrosis factor (TNF)-α therapy, viral, 518
gene structure and variations, 1937, 1959 285, 1071, 1359 hereditary
mutations, 1959 AOP2 (antioxidant protein 2), 790 dyskeratosis congenita, 530–532, 531f,
as protease inhibitor, 1919, 1919t, Aorta-gonad-mesonephros (AGM) region, 531t
1958–1959 54, 100f, 101, 257–258, 1149–1150 Fanconi anemia. See Fanconi anemia
structure, 1936, 1952t Aortic aneurysms, 2210 rare syndromes, 530t, 532
synthesis, 1958 AP1 (activator protein 1), 1606 Shwachman-Diamond syndrome, 532,
Antithrombin (AT) concentrate, 2213 AP3 (activator protein 3) complex, 1843 993–994, 1026
Antithrombin (AT) deficiency AP-3 endosomal protein, 1229 history, 513
acquired causes, 2224t AP1903, 440, 440f laboratory features, 519–520, 519t, 520f
clinical implications of testing for, 2228t Apaf1, 205 monocytopenia in, 1098
epidemiology, 2222t APC. See Activated protein C (APC) paroxysmal nocturnal hemoglobinuria
etiology and pathogenesis, 1937, 1959, APC, 1346 and, 521
2222–2223 APECED (autoimmune polyendocrinopathy- Ph chromosome–positive clonal myeloid
heparin resistance in, 397 candidiasis ectodermal dystrophy), diseases and, 1450
venous thromboembolism risk and, 2225t, 87, 1181, 1224 treatment, 521–527
2226t Apheresis androgens, 526
Antithrombin I. See Fibrinogen for blood component collection and approach to, 521–522, 521t, 525f
Antithrombin III. See Antithrombin (AT) production, 2368–2369, 2386 cytokines, 526
Antithrombotic therapy, 393–406 definition and history, 427 hematopoietic cell transplantation,
adverse effects, 2277 extracorporeal photochemotherapy, 429t, 522–523
antiplatelet drugs. See Antiplatelet drugs 433, 1687 immunosuppressive therapy, 523–526,
in cancer, 2276–2277 leukocytapheresis. See Leukocytapheresis 524t, 525t

Kaushansky_index_p2393-2506.indd 2401 9/21/15 3:21 PM